The FDA Just Gave Nicotine Pouches Their Biggest Regulatory Win Yet

Big Tobacco has had a growth problem for decades. Cigarette volumes fall every year with clock-like regularity, down roughly 2-3% annually as smoking rates decline and older users age out of the market. Now the industry may finally have found the growth engine it has been looking for — and regulators just handed it a powerful marketing tool to go with it.

On June 30, the FDA issued modified risk tobacco product orders for 20 Zyn nicotine pouch products, authorizing Philip Morris International's Swedish Match subsidiary to market them with a specific claim: that switching completely from cigarettes to Zyn lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. It is the first time any nicotine pouch brand has received that designation, and it gives the category something that vaping, heated tobacco, and most alternative nicotine products have never achieved: government-cleared language for the harm-reduction pitch to adult smokers.

The pouch boom in 30 seconds

• US monthly pouch sales: up 250.8% from January 2023 to August 2025
• Global growth since 2020: up 660%
• Global market projection: $25 billion by 2028
• Market leader: Zyn, owned by Philip Morris International
• Main competitors: Altria's On!, British American Tobacco's Velo
• Newest development: FDA authorized Zyn's lower-risk claim for adult smokers switching from cigarettes, June 30, 2026
• Main risk: youth uptake, five-year authorization expiration, long-term health unknowns

Why the FDA decision matters

The FDA's decision did not come out of nowhere. It followed a separate marketing authorization in January 2025, when regulators cleared 20 Zyn products for sale after an extensive scientific review finding substantially lower amounts of harmful chemicals compared with cigarettes and most smokeless tobacco products. The June 30 decision goes further, allowing PMI to make specific disease-risk claims in its marketing.

Zyn is now the first nicotine pouch brand allowed to make that specific lower-risk claim in the US. That matters commercially because it gives the category what no previous oral nicotine product had: FDA-cleared language saying that adult smokers who switch completely face lower risks of specific diseases. The FDA was clear that the authorization covers specific products, not the entire pouch category, that there is no safe tobacco product, and that non-users should not start. The orders also expire in five years, require ongoing postmarket surveillance, and can be withdrawn if the products no longer benefit public health — including if youth uptake rises significantly.

Why Big Tobacco likes the category

The appeal to incumbents goes beyond Zyn's market share. PMI, Altria, and British American Tobacco already own the retail relationships that matter most in this business. Roughly 94% of pouch sales flow through physical retail — convenience stores, gas stations, pharmacies — channels the tobacco companies have dominated for decades.

PMI's smoke-free portfolio, led by pouches, now accounts for 43% of the company's total net revenues, and Zyn consumer sales grew more than 10% in Q1 2026 even as shipments fell due to inventory normalization. Altria's On! shipped 177.8 million cans in 2025, up 11%. Startups are trying to break in, but the incumbents' distribution advantage is substantial and the FDA's modified-risk pathway requires extensive scientific investment that favors well-resourced players.

The regulatory catch

The same FDA that just gave Zyn a landmark authorization has also moved slowly on new product approvals precisely because of concerns about creating new nicotine addicts — particularly among people who never smoked.

Youth usage is currently modest but not meaningless. The FDA's own June 2026 review cited data showing approximately 1.7% of middle and high school students currently use nicotine pouches. Public health advocates note that the trajectory matters: a category growing at 250% over two years, now authorized to market itself as lower-risk than cigarettes, could rapidly expand youth uptake if marketing dynamics shift.

That is the scenario that ended the first wave of flavored e-cigarettes. Juul grew explosively, attracted youth users at scale, and then faced a regulatory crackdown that forced reformulations, pulled products, and imposed enormous legal liability. The structural parallel to pouches is not exact, but the basic dynamic is recognizable: fast growth, flavor variety, youth accessibility, and an industry arguing it is helping adults quit smoking. The FDA's five-year authorization window and postmarket surveillance requirements reflect exactly this concern.

What to watch

• Modified-risk marketing in practice: Watch whether Zyn's FDA-cleared lower-risk language meaningfully accelerates sales among adult smokers switching categories, and whether the FDA eventually extends MRTP authorization to competing brands.
• Youth usage data: Any significant increase in pouch use among teenagers would accelerate regulatory intervention. The FDA flagged this concern explicitly in its June 30 authorization.
• FDA speed on new authorizations: Altria and BAT are waiting on authorization for additional products. The pace of new approvals will shape how competitive the field becomes.
• International expansion: PMI is expanding Zyn across more than 100 markets. European and Asian regulatory environments vary widely and represent the next major growth frontier.

The bottom line

Cigarette volumes are still shrinking. Nicotine pouches are still booming. And the FDA's June 30 decision gives Zyn something rare in tobacco: permission to make a specific lower-risk claim to adult smokers who switch completely from cigarettes.

That could make pouches Big Tobacco's most credible growth engine in years. But the risk is obvious. If regulators view pouches as a genuine harm-reduction tool for adult smokers, PMI and its rivals have a durable tailwind. If youth usage rises, the category could face the same kind of backlash that hit vaping.

The growth story is real. So is the regulatory tripwire.

Sources

• FDA, FDA authorizes 20 Zyn nicotine pouches to be marketed with specific modified risk claim: https://www.fda.gov/tobacco-products/ctp-newsroom/fda-authorizes-20-zyn-nicotine-pouches-be-marketed-specific-modified-risk-claim
• Business Wire / PMI, FDA issues modified risk tobacco product orders for 20 Zyn nicotine pouch products: https://www.businesswire.com/news/home/20260630053034/en/FDA-Issues-Modified-Risk-Tobacco-Product-Orders-for-20-ZYN-Nicotine-Pouch-Products
• Fox Business, Nicotine pouches surge in popularity: https://www.foxbusiness.com/lifestyle/nicotine-pouches-surge-popularity-diplo-celebrity-investors-bet-industrys-future
• STOP, New report — nicotine pouch market has exploded: https://exposetobacco.org/news/new-report-nicotine-pouch-market-has-exploded/
• CSP Daily News, FDA allows Zyn to market nicotine pouches as safer alternative to cigarettes: https://www.cspdailynews.com/tobacco/fda-allows-zyn-market-nicotine-pouches-safer-alternative-cigarettes
• PMI, Philip Morris International reports 2026 first-quarter results: https://www.pmi.com/investor-relations/press-releases-and-events/press-releases-overview/press-release-details?newsId=29931
• Yahoo Finance / Seeking Alpha, Altria's best growth opportunity is running into bureaucratic foot-dragging: https://finance.yahoo.com/sectors/healthcare/articles/altria-best-growth-opportunity-running-154337429.html